GLP-1 Medications Linked to Lower Rates of Multiple Sclerosis Relapse in Real-World Study

A large real-world observational study presented at a major medical conference suggests that multiple sclerosis patients exposed to GLP-1 receptor agonist medications experienced lower rates of relapse activity and steroid use compared with unexposed individuals. The findings were detailed by Dr. Mahsa Khayat-Khoei of the University of California Riverside at MSToronto2026, the joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis and the Americas Committee for Treatment and Research in Multiple Sclerosis.

Evaluating Real-World Data on GLP-1 Use

The analysis examined data utilizing the TriNetX research network, identifying patients through diagnostic codes. Over a 12-year observation window, researchers tracked clinical outcomes among individuals with multiple sclerosis. Patients who used GLP-1 receptor agonists showed a lower frequency of acute steroid-treated relapses, dropping to 1.85% compared with 4.84% in the control group. Furthermore, researchers observed a reduced incidence of optic neuritis at 1.46% versus 2.56%, alongside fewer overall demyelinating events at 3.48% compared to 7.01%.

The study also reported lower rates of secondary symptoms among the GLP-1 cohort, including reduced occurrences of gait abnormalities, fatigue, and depression. A specific subgroup analysis focusing on patients receiving the B-cell therapy ocrelizumab demonstrated similar protective patterns, displaying notable relative risk reductions in acute steroid-treated relapses and optic neuritis episodes over a ten-year observation period.

Potential Mechanisms and Biological Rationale

GLP-1 receptor agonists are primarily approved for managing type 2 diabetes and obesity. However, researchers note that these agents may influence neurological pathways through the gut-brain axis. Experts unaffiliated with the study suggest that these medications could impact insulin signaling, mitochondrial resilience, vascular function, and neuroinflammation, offering a plausible biological basis for ongoing neurological investigation.

Dr. Paul Edison of Imperial College London, who did not participate in the research, noted that while the observational data are encouraging, different GLP-1 analogues possess varying molecular structures, central actions, and receptor engagements. Prior clinical evaluations of GLP-1 drugs in other neurodegenerative conditions have yielded mixed results, emphasizing that findings across different neurological disorders can vary significantly depending on the specific analogue tested.

Study Limitations and Next Steps

Study authors emphasized important limitations within the real-world design. Patients in the GLP-1 group presented with higher baseline body mass indices and significantly higher rates of type 2 diabetes and obesity. Although researchers utilized propensity-score matching to account for age, sex, and comorbidities, observational studies cannot definitively establish direct causation.

Because the current findings are preliminary and derived from retrospective database tracking rather than randomized controlled trials, experts agree that prospective clinical studies are urgently required. Future investigations will help determine whether GLP-1 receptor agonists truly possess disease-modifying or neuroprotective properties for individuals living with multiple sclerosis.

• Observational study links GLP-1 exposure to fewer multiple sclerosis relapses.
• Researchers used propensity-score matching to control for baseline health differences.
• Prospective clinical trials are necessary to confirm potential neuroprotective benefits.